{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:49:56Z","timestamp":1793321396607,"version":"4.5.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,28]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Bu4\/Cy, Flu\/Bu4, and Flu\/Mel are optimal regimens for patients with AML in clinical remission or those with MDS. Flu\/Mel, considered a less-intense regimen, is ideal for less fit patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018021980","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T16:46:43Z","timestamp":1536943603000},"page":"2095-2103","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":79,"title":["Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity"],"prefix":"10.1182","volume":"2","author":[{"given":"Mary","family":"Eapen","sequence":"first","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Brazauskas","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hemmer","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleska S.","family":"Perez","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Steinert","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"issue":"12","key":"2019111617265806000_B1","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","article-title":"Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"2019111617265806000_B2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.leu.2404010","article-title":"Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis","volume":"20","author":"Scott","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"2019111617265806000_B3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2019111617265806000_B4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111617265806000_B5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","article-title":"Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome","volume":"12","author":"Alyea","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2019111617265806000_B6","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringd\u00e9n","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111617265806000_B7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111617265806000_B8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial","volume":"13","author":"Bornh\u00e4user","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111617265806000_B9","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111617265806000_B10","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC Trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111617265806000_B11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.mayocp.2013.07.012","article-title":"The necessity for clinical reasoning in the era of evidence-based medicine","volume":"88","author":"Sniderman","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"9422","key":"2019111617265806000_B12","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(04)16261-2","article-title":"When are observational studies as credible as randomised trials?","volume":"363","author":"Vandenbroucke","year":"2004","journal-title":"Lancet"},{"key":"2019111617265806000_B13","author":"Fisher","year":"1990"},{"issue":"6","key":"2019111617265806000_B14","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111617265806000_B15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"8","key":"2019111617265806000_B16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","article-title":"Non-parametric inference for cumulative incidence functions in competing risks studies","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"issue":"2","key":"2019111617265806000_B17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"12","key":"2019111617265806000_B18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","article-title":"Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests","volume":"18","author":"Andersen","year":"1999","journal-title":"Stat Med"},{"issue":"15","key":"2019111617265806000_B19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"25","key":"2019111617265806000_B20","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","article-title":"Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"117","author":"Soiffer","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111617265806000_B21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111617265806000_B22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2019111617265806000_B23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbmt.2007.01.079","article-title":"Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation","volume":"13","author":"Armand","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111617265806000_B24","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood-2012-04-423046","article-title":"Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS","volume":"120","author":"Deeg","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2019111617265806000_B25","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111617265806000_B26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/16\/2095\/881813\/advances021980.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/16\/2095\/881813\/advances021980.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T06:25:48Z","timestamp":1720592748000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/16\/2095\/15935\/Hematopoietic-cell-transplant-for-acute-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,8,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018021980","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,22]]}}}